Home > Result Summaries: Compounds > abacavir > Result Summary for COL30573

Result Summary for COL30573

Result Summary

Protocol ID:	COL30573
Clinical Study ID:	COL30573
Official Title:	Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection
Phase:	Phase 4
Study Indications or Diseases:	Infection, Human immunodeficiency Virus
Generic Name:	abacavir
Trade/Product Name:	ziagen;ziagen
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Fisac C, et al. Metabolic Benefits 24 Months After Replacing a Protease Inhibitor with Abacavir, Efavirenz, or Nevirapine. . AIDS 2005, 19:917-925.. Martinez E, et al. Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection. N Engl J Med 2003; 349:1036-46. De Echagüen A, et al. Genotypic and Phenotypic Resistance Patterns at Virological Failure in a Simplification Trial with Nevirapine, Efavirenz, or Abacavir. AIDS 2005; 19:1385-1391.